Federal Trade Commission sues largest drug middlemen for allegedly inflating insulin prices

​ The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies of “engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs, impaired patients’ access to lower list price products, and shifted the cost of high insulin list prices to vulnerable patients.” Read More Breaking News, Latest News and Videos | CNN